Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|April 11, 2024
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)Alessandro Cafaro, Flavia Foca, Oriana Nanni, et al.
Risk Management and Healthcare Policy|March 3, 2026
An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration for Lung Cancer Patients Treated in a Day Hospital SettingAlessandro Morabito, Piera Maiolino, Stefania D'Auria, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
Nutrients|March 14, 2026
Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN ProjectGiuseppe Porciello, Anna Crispo, Francesco Pio Maria Di Carlo, et al.
BMC Cancer|November 26, 2016
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trialFrancesco Caponigro, Elena Di Gennaro, Franco Ionna, et al.
Journal of Xenobiotics|January 21, 2026
Cross-Sectional Multicenter Biomonitoring Study on Genotoxicity and Oxidative DNA Damage in Oncology Healthcare Workers from Seven Italian HospitalsCinzia Lucia Ursini, Giorgia Di Gennaro, Giuliana Buresti, et al.
Oncotarget|October 6, 2017
Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidencesVincenzo Quagliariello, Sabrina Rossetti, Carla Cavaliere, et al.
Oncotarget|April 9, 2017
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidencesVincenzo Quagliariello, Sabrina Rossetti, Carla Cavaliere, et al.
Oncotarget|April 27, 2017
Micrornas in prostate cancer: an overviewDaniela Vanacore, Mariarosaria Boccellino, Sabrina Rossetti, et al.
Oncotarget|November 9, 2016
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewFrancesco Jacopo Romano, Sabrina Rossetti, Vincenza Conteduca, et al.
Pageof 6